Cyclic Amyloid-Beta-Binding Peptides and Their Use

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention relates to cyclic peptides that specifically bind to amyloid-beta (Aβ) species, which are closely linked to the progression of Alzheimer's disease. By engineering these peptides into a cyclic form (as opposed to linear), their binding affinity, stability, and effectiveness in neutralizing or preventing the formation of toxic Aβ oligomers and aggregates are greatly enhanced. These cyclic peptides can be used for both therapeutic purposes (treating or preventing Alzheimer's) and as molecular probes for early diagnosis through imaging techniques.

Use CasesContent extracted from patent full text and abstract with AI.

• Therapeutic treatment to prevent or neutralize toxic amyloid-beta oligomers in Alzheimer's disease patients.
• Development of drugs or formulations that use these cyclic peptides to slow or halt progression of Alzheimer's disease.
• Use as molecular imaging probes for early detection and diagnosis of Alzheimer's disease, even before symptom onset, via PET, MRI, or other imaging modalities.
• Monitoring and follow-up of disease progression and response to therapy in Alzheimer's patients.
• Potential application in other neurodegenerative diseases where amyloid or protein aggregation is a factor (e.g., Parkinson's, ALS, Creutzfeldt-Jakob disease).
• Diagnostic kits incorporating these peptides for laboratory or clinical use.

BenefitsContent extracted from patent full text and abstract with AI.

• The cyclic form of the peptides offers significantly higher binding affinity for amyloid-beta species (including toxic oligomers) than comparable linear peptides.
• Cyclic peptides are more stable in physiological conditions, making them more resistant to enzymatic degradation and therefore more effective in the body.
• Potential to enable earlier and more accurate diagnosis of Alzheimer’s disease through imaging, allowing intervention before irreversible brain damage occurs.
• Can be used in all disease stages, from early prevention to intervention after symptom onset.
• Offers both therapeutic (disease-modifying) and diagnostic (imaging/biomarker) applications, with the same core molecular scaffold.
• The modular design allows for optimization and adaptation to different forms or aggregates of amyloid-beta.
• May reduce side effects and dosing frequency due to higher stability and affinity, improving patient compliance.
• Could inform the development of vaccines or preventive treatments against Alzheimer's disease.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to a peptide comprising at least one peptide which binds to an amyloid-beta species. The peptide has an amino acid sequence which is present in cyclized form. The invention also relates to the use of the peptides in the medical field, in particular for the treatment of Alzheimer's disease.